Grupo Casa Saba To Acquire FASA in Landmark Latin American Pharmaceutical Transaction
18 Mai 2010 - 2:00PM
Business Wire
Grupo Casa Saba, S.A.B. de C.V. ("GCS") (NYSE: SAB) (BMV: SAB*),
and various Chilean legal entities that are controlled by Mr. José
Codner Chijner, who is the final controller of Farmacias Ahumada
S.A. ("FASA") (BCS: FASA) announced that they have reached a
definitive agreement under which GCS will acquire the control of
FASA in a transaction valued at approximately US$637 million,
including the assumption of US$162 million in estimated net debt as
of March 31, 2010.
Under the terms of the agreement and at the request of Mr.
Codner, GCS will offer an all cash option tender for 100% of FASA
common shares, which trade on the Bolsa de Comercio de Santiago, at
a price of CLP 1,642 per share. The tender offer will be contingent
upon the successful tender of at least 50.0% plus one of all FASA
shares outstanding, and is expected to be financed through a mix of
cash and new debt for which GCS has obtained firm commitments from
HSBC.
The combined company, which will be consolidated under GCS, will
become the leading drugstore chain in Latin America and one of the
largest distributors of consumer and pharmaceutical products in the
region, with estimated pro-forma revenues of approximately US$4
billion and a wide platform of c. 1500 drugstores across Mexico,
Brazil, Chile and Peru.
Manuel Saba, Chairman of the Board of GCS, said, "This
transformational transaction is of critical importance for GCS’s
strategic future and long-term prospects for value creation. We
have spent years focused on building a best-in-class wholesale
pharmaceutical distribution platform and preparing for the
strategic expansion of our business across Latin America. We have
successfully built a business model with clear and sustainable
competitive advantages based on a deep, experienced and dedicated
team and state-of-the art technology. The synergies, productivity
gains, and organic growth prospects moving forward are staggering.
At this defining moment, we look forward to forging a clear path
for GCS to become the Latam bellwether in the space and to seek
accretive organic and non-organic opportunities across the region
and building upon the tremendous success that FASA and GCS have
accomplished until now.”
The transaction has been approved by the Boards of Directors of
GCS and will be subject to the satisfactory completion of certain
conditions. Such conditions include the approval of a majority of
GCS shareholders, customary regulatory approvals (including the
anti-trust authority in Mexico), and other customary closing
conditions.
HSBC and Estructura Partners/Cicerone acted as joint financial
advisors to GCS in connection with this transaction. The sellers
were advised by Goldman Sachs & Co. and Servicios Financieros
ALTIS S.A.
About GCS
GCS was founded as a pharmacy in 1892, and is currently one of
the leading multi-channel, multi-product national wholesale
distributors in Mexico, operating through one of Mexico’s largest
nationwide distribution networks of its type with US$2.2 billion in
sales in 2009. GCS distributes pharmaceutical products, health,
beauty aids and consumer goods, general merchandise, publications
and other products. The majority of these products are distributed
on a non-exclusive basis. GCS also owns and operates a chain of 160
drugstores under the Farmacias ABC brand in Mexico and 96
drugstores in the States of Rio de Janeiro and Sao Paulo in Brazil.
With over 115 years of experience, GCS serves a significant number
of Mexico’s pharmacies, mass merchandisers, retail and convenience
stores, supermarkets and other specialized channels.
About FASA
FASA was founded by José Codner in 1969, and is the largest
drugstore operator in Latin America with US$1.65 billion in sales
in 2009. FASA has a footprint of over 1240 drugstores across Chile,
Mexico and Peru. During 2009, FASA served over 217 million
customers in these three countries, successfully delivering top of
the line customer experience and superb pharmaceutical attention.
FASA has a 40-year track record of value creation and is today the
largest and most modern drugstore chain in Latin America. Its
stores offer a wide assortment of pharma, health & beauty,
personal care and convenience consumer products.
Forward-Looking Statements
This press release contains certain "forward-looking statements"
within the meaning of Section 21E of the Securities and Exchange
Act of 1934, as amended. These forward-looking statements relate to
GCS, FASA, their respective businesses, the proposed combined
company and the transactions and are based on GCS’s and FASA's
managements current expectations. Readers are cautioned not to put
undue reliance on such forward-looking statements, which are not a
guarantee of performance and are subject to a number of
uncertainties and other factors, many of which are outside GCS’s
and FASA’s control, that could cause actual results of GCS, FASA,
or the combined company to differ materially from such statements.
Factors that may cause or contribute to such differences include
adverse regulatory developments, deterioration in relationships
with suppliers, the imposition of voluntary price restraints or
statutory price controls by any government, increased competition
in the markets for pharmaceutical, health & beauty, personal
care and other consumer products, more stringent environmental
regulations, exchange rate fluctuations, high levels of inflation
and other risks.
The proposed transaction, the financial condition and results of
the combined company will be subject to numerous risks and
contingencies, including successful regulatory approvals, the
ability to realize synergies and successfully integrate operations.
None of GCS and FASA is under any obligation, and GCS and FASA
expressly disclaim any intention or obligation, to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
This press release includes unaudited pro forma financial
information that relates to the transaction. However, this
information is preliminary, not in accordance with generally
accepted accounting principles and not necessarily indicative of
historical financial position or of any future financial data.
Saratoga Investment (NYSE:SAB)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Saratoga Investment (NYSE:SAB)
Historical Stock Chart
Von Dez 2023 bis Dez 2024